Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
|Official Title:||Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism|
- ADHD symptoms [ Time Frame: Measured at Weeks 2 and 4 and 6 and 8 ] [ Designated as safety issue: No ]
- Irritability and anxiety [ Time Frame: Measured at Weeks 2 and 4,and 6, and 8 ] [ Designated as safety issue: Yes ]
- Core autistic symptoms [ Time Frame: Measured at Weeks 2 and 4, and 6 and 8 ] [ Designated as safety issue: No ]
- Quality of life [ Time Frame: Measured at Weeks 2 and 4 and 6 and 8 ] [ Designated as safety issue: No ]
|Study Start Date:||July 2007|
|Estimated Study Completion Date:||October 2015|
|Estimated Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
Other Name: Strattera
Placebo Comparator: 2
Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
Autism is a developmental disorder that can cause severe and pervasive impairment in thinking, feeling, language, and the ability to relate to others. It is usually first diagnosed in early childhood. Children with autism demonstrate repetitive behaviors or interests and deficits in social interaction, verbal communication, and nonverbal communication. In addition, they often have unusual responses to sensory experiences, such as certain sounds or the way objects look. Some symptoms of attention deficit hyperactivity disorder (ADHD), such as inattention, hyperactivity, and impulsivity, are also associated with autism. Atomoxetine is a selective norepinephrine reuptake inhibitor that is used to treat ADHD. It works differently, however, than stimulant drugs and may help to reduce ADHD symptoms in children with autism. This study will evaluate the effectiveness of atomoxetine in treating children with ADHD symptoms associated with autism.
Potential participants will first attend a screening visit, which will include a psychiatric diagnostic interview, a practice session for swallowing pill capsules, a physical exam, an electrocardiogram (ECG), a blood test, and an assessment of pubertal stage. Females of childbearing age will also undergo a urine pregnancy test. In an initial double-blind study phase, eligible participants will be randomly assigned to receive either atomoxetine or placebo for 8 weeks. A baseline visit will include several rating scales, observations, and an interview to assess adaptive functioning. These measures and procedures will be used to keep track of symptoms, side effects, and behavior that could change during the study. Children who are assigned to placebo and do not notice an improvement in their ADHD symptoms will be given the opportunity to receive atomoxetine at the end of 8 weeks. Study visits will occur once a week for 4 weeks, and then every other week for the remainder of the 8 weeks. During these visits, many of the baseline questionnaires and interviews will be repeated. At the Week 8 visit, the physical exam, ECG, blood tests, and some baseline questionnaires will also be repeated. All children who respond well to atomoxetine may continue taking the drug for an additional 10 months. During this time, participants will report to the clinic once a month for the first 4 months, then once at the end of 7 months, and finally once at the end of 10 months. The same measures and procedures that were done during the 8-week phase will be done during the 10-month phase of this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00498173
|Contact: Jennifer Mullett, RN, CCRP||781-860-1711||LurieCenterResearch@partners.org|
|United States, Indiana|
|Christian Sarkine Autism Treatment Center at Riley Hospital for Children||Completed|
|Indianapolis, Indiana, United States, 46202|
|United States, Massachusetts|
|Lurie Center - MassGeneral Hospital||Recruiting|
|Lexington, Massachusetts, United States, 02421|
|Contact: Jennifer Mullett, RN, CCRP 781-860-1711 LurieCenterResearch@partners.org|
|Principal Investigator: Christopher J McDougle, MD|
|Principal Investigator:||Christopher J. McDougle, MD||Massachusetts General Hospital|